| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ATG4A |
| Uniprot No | Q8WYN0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-398aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMESVLSKYEDQITIFTDYLEEYPDTDELVW ILGKQHLLKTEKSKLLSDISARLWFTYRRKFSPIGGTGPSSDAGWGCMLR CGQMMLAQALICRHLGRDWSWEKQKEQPKEYQRILQCFLDRKDCCYSIHQ MAQMGVGEGKSIGEWFGPNTVAQVLKKLALFDEWNSLAVYVSMDNTVVIE DIKKMCRVLPLSADTAGDRPPDSLTASNQSKGTSAYCSAWKPLLLIVPLR LGINQINPVYVDAFKECFKMPQSLGALGGKPNNAYYFIGFLGDELIFLDP HTTQTFVDTEENGTVNDQTFHCLQSPQRMNILNLDPSVALGFFCKEEKDF DNWCSLVQKEILKENLRMFELVQKHPSHWPPFVPPAKPEVTTTGAEFIDS TEQLEEFDLEEDFEILSV |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ATG4A重组蛋白的3篇参考文献示例(注：文献信息为虚构，仅供示例参考)：
---
1. **文献名称**：*Recombinant ATG4A Expression and Its Role in LC3 Processing*
**作者**：Li X, et al.
**摘要**：本研究在大肠杆菌系统中成功表达并纯化重组人ATG4A蛋白，验证其具有切割LC3前体的酶活性，并通过突变实验证明Cys74为关键催化位点，为自噬调控机制研究提供工具。
2. **文献名称**：*Structural Insights into ATG4A Protease Activity via Crystallography*
**作者**：Wang Y, et al.
**摘要**：通过X射线晶体学解析重组ATG4A的三维结构，揭示其底物结合口袋的特征，并发现ATP结合对其构象的调控作用，为开发自噬相关疾病药物奠定结构基础。
3. **文献名称**：*ATG4A Recombinant Protein Screening for Autophagy Modulation in Cancer*
**作者**：Zhang R, et al.
**摘要**：利用重组ATG4A蛋白建立高通量抑制剂筛选平台，发现小分子化合物NP-12可抑制ATG4A活性，从而阻断肿瘤细胞自噬通路，增强化疗敏感性。
---
**备注**：以上文献为模拟示例，实际研究需通过PubMed或Web of Science检索真实论文(关键词：ATG4A recombinant, autophagy protease, LC3 processing)。
ATG4A, a member of the ATG4 cysteine protease family, plays a pivotal role in autophagy, a conserved cellular recycling process. This enzyme specifically cleaves proLC3 (microtubule-associated protein 1A/1B-light chain 3) to generate LC3-I, which is subsequently conjugated to phosphatidylethanolamine (PE) to form LC3-II—a critical step in autophagosome membrane formation. ATG4A also mediates LC3 delipidation during autophagosome maturation and cargo degradation, ensuring autophagy flux homeostasis. Dysregulation of ATG4A has been implicated in various pathologies, including cancer, neurodegenerative diseases, and metabolic disorders, making it a key therapeutic target.
Recombinant ATG4A protein is engineered using expression systems like E. coli or mammalian cells to produce high-purity, catalytically active enzymes for research and drug discovery. Its production involves cloning the human ATG4A gene into expression vectors, followed by purification via affinity chromatography and functional validation using LC3 processing assays. This recombinant tool enables detailed studies of autophagy mechanisms, screening for modulators (activators/inhibitors), and exploration of disease-related autophagy defects. Recent studies highlight its potential in cancer therapy, where ATG4A inhibitors may sensitize tumor cells to chemotherapy by blocking pro-survival autophagy. However, challenges remain in understanding isoform-specific functions (ATG4A/B/C/D) and developing selective regulators. Current research focuses on resolving its structural dynamics and substrate interactions to guide targeted drug design. As autophagy gains prominence in aging and immunity research, recombinant ATG4A serves as an essential reagent for decoding its biological significance and translational applications.
×
